COMPANY: Starpharma

Overview
Starpharma Holdings Ltd. claims to be the world leader in using dendimer-based nanotechnology for pharmaceutical development. Starpharma was founded in 1996 out of the Biomolecular Research Institute (BRI) and is currently traded on the Australian Stock Exchange (ASX). The company specializes in using dendrimer technology to create pharmaceuticals aiding in the prevention of STDs, including herpes and HIV. Starpharma has received over $20M in government grants (NIH) and recently acquired Dendritic Nanotechnologies (DNT) in order to strengthen research into further denrimer applications. Starpharma has a market cap of around $89M.

Starpharma.com

Products
VivaGelTM - This gel-based STD preventative is the most advanced of Starpharma's pharmaceuticals. VivaGel has successfully tested in Phase I clinical trials and is currently testing in the US, Australia, and Kenya. Based on its potentially critical role in preventing STDs, the FDA has granted VivaGel Fast Track status through its regulatory process.

News
10.10.2006- Starpharma acquired DNT for approximitely $14M. The acquisition provides Starpharma with strengthened control over primary dendrimer development and gives Starpharma ownership over additional dendrimer patents, making Starpharma the leader in holding such patents. Starpharma had previously held a 33% stake in DNT.

1.9.2006- VivaGel received Fast Track status from the FDA.

10.3.2005- Starpharma received $20M from the NIH to further develop VivaGel.

4.1.2005- Starpharma received AUD$5.7M from the Australian government to pursue dendrimer-based pharmaceutical development.